CIPLA2021-10-012021-12-31in-bse-fin:OneOperatingExpenses01Member CIPLA2021-10-012021-12-31in-bse-fin:FourOperatingExpenses01Member CIPLA2021-10-012021-12-31in-bse-fin:OneReportableSegmentRevenue01Member CIPLA2021-10-012021-12-31in-bse-fin:OneReportableSegmentRevenue02Member CIPLA2021-10-012021-12-31in-bse-fin:FourReportableSegmentRevenue01Member CIPLA2021-10-012021-12-31in-bse-fin:FourReportableSegmentRevenue02Member CIPLA2021-10-012021-12-31in-bse-fin:OneReportableSegmentResults01Member CIPLA2021-10-012021-12-31in-bse-fin:OneReportableSegmentResults02Member CIPLA2021-10-012021-12-31in-bse-fin:FourReportableSegmentResults01Member CIPLA2021-10-012021-12-31in-bse-fin:FourReportableSegmentResults02Member CIPLA2021-10-012021-12-31in-bse-fin:OneReportableSegmentAssets01Member CIPLA2021-10-012021-12-31in-bse-fin:OneReportableSegmentAssets02Member CIPLA2021-10-012021-12-31in-bse-fin:OneReportableSegmentLiabilities01Member CIPLA2021-12-31in-bse-fin:OneReportableSegmentLiabilities01Member CIPLA2021-10-012021-12-31in-bse-fin:OneReportableSegmentLiabilities02Member CIPLA2021-12-31in-bse-fin:OneReportableSegmentLiabilities02Member CIPLA2021-10-012021-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member CIPLA2021-10-012021-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member CIPLA2021-10-012021-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member CIPLA2021-10-012021-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares CIPLA 2021-04-01 2022-03-31 2021-12-30 INR Crores Third quarter Multi segment 2021-10-01 2021-12-31 Unaudited Consolidated 54788600000.00 912900000.00 55701500000.00 15247600000.00 7166300000.00 -980200000.00 8724300000.00 206800000.00 2474700000.00 12320900000.00 45160400000.00 10541100000.00 0.00 10541100000.00 3080000000.00 -128400000.00 2951600000.00 0.00 7589500000.00 0.00 0.00 0.00 -20700000.00 7568800000.00 -705100000.00 6863700000.00 7286000000.00 282800000.00 6586900000.00 276800000.00 1613600000.00 2 9.03 9.02 0.00 0.00 9.03 9.02 Due to space constraints the notes cannot be provided in the XBRL utility. Please refer the PDF file of Financial Results uploaded on 25th January 2022 for notes to accounts. Multi segment 2021-04-01 2021-12-31 Unaudited Consolidated 165030100000.00 2168900000.00 167199000000.00 43212100000.00 29401200000.00 -9124300000.00 26375000000.00 882500000.00 7616400000.00 37135500000.00 135498400000.00 31700600000.00 -1246200000.00 30454400000.00 9065600000.00 -438700000.00 8626900000.00 0.00 21827500000.00 0.00 0.00 0.00 -68000000.00 21759500000.00 126700000.00 21886200000.00 21546800000.00 212700000.00 21613700000.00 272500000.00 1613600000.00 2 26.71 26.68 0.00 0.00 26.71 26.68 Other expenses 12320900000.00 Other expenses 37135500000.00 New ventures 1270900000.00 Pharmaceuticals 53772800000.00 New ventures 4209200000.00 Pharmaceuticals 161753200000.00 55043700000.00 165962400000.00 255100000.00 932300000.00 54788600000.00 165030100000.00 New ventures -233300000.00 Pharmaceuticals 10981200000.00 New ventures -982500000.00 Pharmaceuticals 33565600000.00 10747900000.00 32583100000.00 206800000.00 882500000.00 0.00 As certain assets and liabilities are deployed interchangeably across segments, it is not practically possible to allocate those assets and liabilities to each segment. Hence, the details of assets and liabilities have not been disclosed in the above table. 1246200000.00 10541100000.00 30454400000.00 New ventures 0.00 Pharmaceuticals 0.00 0.00 New ventures 0.00 Pharmaceuticals 0.00 0.00 0.00 0.00